Last edition
News about "Positive results from phase 2/3 XIRIUS study of ge"
Biogen Inc. announced topline results from the phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP)
Positive Results From Phase 2/3 XIRIUS Study Of Ge | 17/05/2021 | By Darshana | 855
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members